Preferred Label : Aganirsen;
NCIt definition : A 25-mer antisense oligonucleotide (ASO) that targets the mRNA transcript for insulin
receptor substrate (IRS-1), a protein required for the formation and growth of new
blood vessels, that can be used to reduce corneal angiogenesis and neovascularization.
Upon ocular administration, aganirsen binds to IRS-1 mRNA and blocks the synthesis
of IRS-1. By blocking the expression of IRS-1 in pro-angiogenic conditions, such as
those seen in corneal grafts and other inflammatory-based ocular diseases, aganirsen
blocks the corneal neovascularization pathway, inhibits vascular endothelial growth
factor (VEGF) production, which is a key component of neovascularization, and prevents
the production of various pro-inflammatory cytokines, which together decrease the
risk of corneal neovascularization. Additionally, upon corneal transplantation, neovascularization
induces an immune response that can lead to immunological corneal graft rejection;
therefore, by inhibiting neovascularization this agent can decrease the risk of corneal
graft rejection. IRS-1, overexpressed in endothelial cells during corneal neovascularization,
plays a key role in the regulation of angiogenesis.;
UNII : 0N3FY8225K;
CAS number : 1146887-67-3;
Molecule name : GS-101;
Origin ID : C148131;
UMLS CUI : C3852710;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
